CXCR4 gene disrupted T cells (Scripps Research Institute/Sangamo)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug NameCXCR4 gene disrupted T cells (Scripps Research Institute/Sangamo)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionC-X-C motif chemokine receptor 4 antagonists
TargetsC-X-C motif chemokine receptor 4
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe Scripps Research Institute Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSangamo Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A